<DOC>
	<DOCNO>NCT02844283</DOCNO>
	<brief_summary>This first clinical trial use Ad-HGF gene treatment myocardial infarction disease .</brief_summary>
	<brief_title>Ad-HGF Treatment Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Male female 1880 year age Clinical diagnosis anterior STsegment elevation myocardial infarction ( STEMI ) within last 30 day , one follow 12lead electrocardiographic change : ) Greater equal 2 mm STsegment elevation ) 2 adjacent electrocardiographic precordial lead b ) A new left bundle branch block AND increase cardiospecific enzymes &gt; 3x CK , increase troponin compare institution laboratory normal range Successful PCI stent implantation infarctrelated artery within last 30 day ; define residual stenosis great 30 % , Thrombolysis In Myocardial Infarction ( TIMI ) flow least 2 reference diameter least &gt; 2mm Is consider hemodynamically stable time enrollment immediately prior AdHGF delivery Screening LVEF first 12 enrolled participant , must great 40 % echocardiography ( determined Simpson 's method ) perform least 2 day revascularization procedure . Subsequent participant enrol trial , must LVEF great 45 % . ( All screening echo do within first 4 day post percutaneous coronary intervention ( PCI ) must repeat either echocardiography MRI prior AdHGF delivery ensure variability exceed 10 % ) In case previous myocardial infarction , document LVEF must 50 % great Female participant must surgically sterile , postmenopausal , document infertility , childbearing potential wih laboratory confirmation nonpregnant state Provided write informed consent willing comply study followup visit Significant unprotected leave main disease ( stenosis 50 % great ) diagnostic angiography An increase LVEF great 10 % initial LVEF evaluation repeat assessments The presence significant coronary lesion , index lesion infarction relate artery A history significant ventricular arrhythmia relate index STEMI A history cerebrovascular accident transient ischemic attack within 6 month enrollment Inability undergo apheresis procedure ( i.e . : poor venous access , laboratory abnormality A history uncorrected significant valvular heart disease A history leave ventricular dysfunction prior index STEMI A history human immunodeficiency virus ( HIV ) hepatitis B C infection A history malignancy within 5 year ( Except lowgrade fully resolve nonmelanoma skin cancer ) A history allergy gentamycin amphotericin A history noncompliance Active inflammatory autoimmune disease require chronic immunosuppressive therapy Creatinine clearance &lt; 60 CockcroftGault Calculator Confirmed pregnant lactating Is enrol current investigational drug device trial Participant receive cell gene therapy past The presence significant comorbidities , investigator 's opinion , would preclude participant take part trial Inability provide inform consent comply followup visit schedule</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HGF , myocardial infarction</keyword>
</DOC>